Literature DB >> 9162089

SHP1 and SHP2 protein-tyrosine phosphatases associate with betac after interleukin-3-induced receptor tyrosine phosphorylation. Identification of potential binding sites and substrates.

H Bone1, U Dechert, F Jirik, J W Schrader, M J Welham.   

Abstract

The cytoplasmic tyrosine phosphatases, SHP1 and SHP2, are implicated in the control of cellular proliferation and survival. Here we demonstrate that both SHP1 and SHP2 associate with the betac subunit of the human interleukin-3 (IL-3) receptor following IL-3 stimulation and that the src homology region 2 (SH2) domains of these phosphatases mediate this interaction. Sequential immunoprecipitation analyses suggest this interaction is direct. Competition studies, using phosphotyrosine-containing peptides based on sequences surrounding key tyrosine residues within betac, suggest that phosphorylation of tyrosine 612 is the key event mediating the association of betac with SHP1 and SHP2. However, inhibition of SHP2 binding to betac, did not prevent tyrosine phosphorylation of SHP2. Interestingly, this same phosphopeptide served as a substrate for the tyrosine phosphatase activity of both SHP1 and SHP2. Binding of these protein-tyrosine phosphatases to the IL-3 receptor may regulate IL-3 signal transduction pathways, both through their catalytic activity and through the recruitment of other molecules to the receptor complex.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9162089     DOI: 10.1074/jbc.272.22.14470

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Proteasomal regulation of betac signaling reveals a novel mechanism for cytokine receptor heterotypic desensitization.

Authors:  M Martinez-Moczygemba; D P Huston
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

Review 2.  Shp1 function in myeloid cells.

Authors:  Clare L Abram; Clifford A Lowell
Journal:  J Leukoc Biol       Date:  2017-06-12       Impact factor: 4.962

Review 3.  The molecular details of cytokine signaling via the JAK/STAT pathway.

Authors:  Rhiannon Morris; Nadia J Kershaw; Jeffrey J Babon
Journal:  Protein Sci       Date:  2018-12       Impact factor: 6.725

4.  Protein tyrosine phosphatase 2 (SHP-2) moderates signaling by gp130 but is not required for the induction of acute-phase plasma protein genes in hepatic cells.

Authors:  H Kim; T S Hawley; R G Hawley; H Baumann
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

5.  New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt pathway.

Authors:  H Gu; H Maeda; J J Moon; J D Lord; M Yoakim; B H Nelson; B G Neel
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

6.  Role of the protein tyrosine phosphatase SHP-1 (Src homology phosphatase-1) in the regulation of interleukin-3-induced survival, proliferation and signalling.

Authors:  Nicholas R D Paling; Melanie J Welham
Journal:  Biochem J       Date:  2002-12-15       Impact factor: 3.857

7.  CoA Synthase is phosphorylated on tyrosines in mammalian cells, interacts with and is dephosphorylated by Shp2PTP.

Authors:  Oksana Breus; Ganna Panasyuk; Ivan T Gout; Valeriy Filonenko; Ivan Nemazanyy
Journal:  Mol Cell Biochem       Date:  2009-09-18       Impact factor: 3.396

8.  Regulation of interleukin-3-induced substrate phosphorylation and cell survival by SHP-2 (Src-homology protein tyrosine phosphatase 2).

Authors:  Helen Wheadon; Christine Edmead; Melanie J Welham
Journal:  Biochem J       Date:  2003-11-15       Impact factor: 3.857

Review 9.  The molecular regulation of Janus kinase (JAK) activation.

Authors:  Jeffrey J Babon; Isabelle S Lucet; James M Murphy; Nicos A Nicola; Leila N Varghese
Journal:  Biochem J       Date:  2014-08-15       Impact factor: 3.857

10.  The Shc-binding site of the betac subunit of the GM-CSF/IL-3/IL-5 receptors is a negative regulator of hematopoiesis.

Authors:  Hayley S Ramshaw; Mark A Guthridge; Frank C Stomski; Emma F Barry; Lisa Ooms; Christina A Mitchell; C Glenn Begley; Angel F Lopez
Journal:  Blood       Date:  2007-07-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.